Taken together, TMB, MSI associated mismatch repair genes, and IPS all predicted that patients in the high risk score group might have a poor immunotherapy response, although the expression of PD-L1/PL-L2 was higher in tumor samples with high risk scores. This evidence concerns the gene CD274 and neoplasm.